PRO-203
Severe Autoimmune Disease
Phase 1Active
Key Facts
About Prolium Bioscience
Prolium Bioscience is a private, clinical-stage biotech emerging from stealth in 2026 with a $50 million launch and a focused pipeline in autoimmune disease. Its lead asset, PRO-203, is a CD20xCD3 T-cell engager already in clinical trials with first patients dosed, positioning it as a potential best-in-class therapy. The company operates with a small, dedicated team and a therapeutics business model, currently in a pre-revenue stage as it advances its novel candidates through development.
View full company profile